The organization indicated that negotiations are underway with "Roche" regarding price reduction, potential donation and equitable distribution around the world.
For the first time, the World Health Organization recommended providing a group of drugs to prevent acute symptoms of "Covid-19" disease in patients at risk due to the disease.
The World Health Organization referred to studies indicating that a combination of kazerifimab and imdivimab, developed by the American company "Regeneron" in partnership with the Swiss company "Roche", could improve patients' chances of survival, according to the German news agency.
WHO is now recommending kazerifimab and imdivimab for pre-existing COVID-19 patients who may have severe symptoms of COVID-19 and face treatment in intensive care units.
The World Health Organization published its new recommendations in the British Medical Journal.
The World Health Organization said in a statement that patients at greater risk of hospitalization and those who did not develop natural antibodies against "Covid-19" are the two groups of patients that benefit most from drug treatment.